Politico published an article that looks at the efforts by nations competing against each other to be the first to produce a COVID-19 vaccine; and warnings that national leaders' desire for bragging rights and fear that another nation will win the race may ultimately undermine the effort to produce a safe, effective vaccine.
In June, Germany paid a whopping sum for a large stake in German drugmaker CureVac, which was developing a Covid-19 vaccine. Piontek was shocked. "Why CureVac?" he thought. The company's vaccine is based on promising but untried and untested technology and its manufacturing capacities are limited. But, months earlier, the American president had insulted German pride by musing about paying CureVac to relocate to the United States. The offer, first reported in the German press under the headline "Trump vs. Berlin," set off outrage in the Bundestag, elicited cries of "Germany is not for sale!" and led the government to shell out 300 million euros for 23 percent of the firm—an unprecedented move.
The strange fate of CureVac shows just how much national pride is defining the lines of the global race for the Covid-19 vaccine. While scientists try to collaborate across national boundaries, national leaders are caught up in an old-fashioned game of one-upmanship—a competition that is driving, and in some cases complicating, the most consequential medical challenge of the 21st century. Public health experts say we should be worried.
Patriotic competitions, however, have dark sides. Friendly races can spur scientists to innovate better and faster, but experts in public health, biotech and national security see many ways today's vaccine nationalism might backfire. It can scramble priorities and lead to bad bets, as Piontek fears. It can goad countries to cheat and take shortcuts, ultimately rolling back progress. A "me first" attitude can also undermine global health. "The danger in vaccine nationalism is that it's not a race to the top, and of sharing, but it's some sort of zero-sum game," warns Ian Goldin, a professor of globalization and development at Oxford University. "That's what we need to guard against."
Loncar doesn't see much of a way out. "One thing that the whole Covid-19 event has taught the world is how important biotech is to society," he says. From now on, "governments are going to view their biotech industries as a component of national security."
The "unprecedented" CureVac investment, he says, is just the beginning of a new era of global competition.
The Dangerous Race for the Covid Vaccine
The international competition for a coronavirus vaccine harkens back to the golden age of Edison and the Wright Brothers. But excesses of national pride and one-upmanship are threatening to overwhelm the common good.
www.politico.com